Medanta delivers record FY26 performance as revenue surges & profit jumps with expansion

Medanta expanded its bed capacity by 20% during the year

Akums posts strong FY26 performance as EBITDA surges 61.6% in Q4

Neuland Laboratories posts blockbuster FY26 performance

Supriya Lifescience delivers robust Q3 FY26 performance with 11% YoY revenue growth

The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25

Aurobindo Pharma reports strong Q3 FY26 performance, boosted by Europe & ARV growth

Aarti Drugs reports strong Q3 FY26 performance, PAT surges 58% YoY

On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY

Glenmark reports robust Q3 FY26 performance, revenues surge 15% YoY

rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million

AstraZeneca's India revenue climbs 33% YoY to Rs. 22.76 billion in FY26

While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications

SMS Pharma posts 48% profit surge in FY26 as margins expand & portfolio shift drives growth

Revenue from operations climbed 13% to Rs. 886.87 crore

Gland Pharma posts record revenue, nearly doubles profit in Q4 FY26

The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment